Harvard Bioscience (HBIO) Amortization of Deferred Charges (2010 - 2026)
Harvard Bioscience (HBIO) posted quarterly Amortization of Deferred Charges of $446000.0 for Q1 2026, up 240.46% year-over-year from $131000.0 in Q1 2025, and down 28.53% quarter-over-quarter from $624000.0 in Q4 2025.
Harvard Bioscience (HBIO) Amortization of Deferred Charges (2010 - 2026) Analysis & Trends
Harvard Bioscience (HBIO) has reported Amortization of Deferred Charges for 17 consecutive years, with $446000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortization of Deferred Charges rose 240.46% year-over-year to $446000.0; the TTM figure through Mar 2026 stood at $1.6 million (up 321.91% YoY), while the FY2025 annual figure was $1.3 million, up 304.28% from the prior year.
- Amortization of Deferred Charges fell to $446000.0 in Q1 2026 per HBIO's latest filing, from $624000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $624000.0 in Q4 2025 and bottomed at $70000.0 in Q1 2022.
- Historically, Amortization of Deferred Charges has averaged $156176.5 across 5 years, with a median of $70000.0 in 2022.
- Annual changes were most pronounced in 2022 — Amortization of Deferred Charges changed 0.0% — and 2025, when it jumped 536.73%.
- Harvard Bioscience's Amortization of Deferred Charges stood at $70000.0 in 2022, then changed by 0.0% to $70000.0 in 2023, then jumped by 40.0% to $98000.0 in 2024, then surged by 536.73% to $624000.0 in 2025, then slipped by 28.53% to $446000.0 in 2026.
- Business Quant data shows HBIO's Amortization of Deferred Charges at $446000.0 in Q1 2026, $624000.0 in Q4 2025, and $357000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn |
| 10 | Harvard Bioscience | 33.45 Mn | 26.94 Mn | 12.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 497,000.00 |
| Jun 30, 2026 | 497,000.00 |
| Mar 31, 2026 | 446,000.00 |
| Mar 31, 2026 | 446,000.00 |
| Dec 31, 2025 | 624,000.00 |
| Dec 31, 2025 | 624,000.00 |
| Sep 30, 2025 | 357,000.00 |
| Sep 30, 2025 | 357,000.00 |
| Jun 30, 2025 | 210,000.00 |
| Jun 30, 2025 | 210,000.00 |
| Mar 31, 2025 | 131,000.00 |
| Mar 31, 2025 | 131,000.00 |
| Dec 31, 2024 | 98,000.00 |
| Dec 31, 2024 | 98,000.00 |
| Sep 30, 2024 | 89,000.00 |
| Sep 30, 2024 | 89,000.00 |
| Jun 30, 2024 | 70,000.00 |
| Jun 30, 2024 | 70,000.00 |
| Mar 31, 2024 | 70,000.00 |
| Mar 31, 2024 | 70,000.00 |